Skip to main content

XEL

Stock

XEL

Stock
Utilities
Utilities - Regulated Electric

Performance overview

XEL Price
Price Chart

Forward-looking statistics

Beta
0.36
Risk
19.60%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Xcel Energy manages utilities serving 3.8 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy owners and suppliers in the US with more than half of its electricity sales coming from carbon-free energy.

Company info

SectorUtilities
IndustryUtilities - Regulated Electric
Employees11K
Market cap$30.4B

Fundamentals

Enterprise value$70.5B
Revenue$13.7B
Revenue per employee—
Profit margin14.10%
Debt to equity163.56

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$3.40
Dividend per share$2.28
Revenue per share$24.13
Avg trading volume (30 day)$215M
Avg trading volume (10 day)$249M
Put-call ratio—

Macro factor sensitivity

Growth+0.2
Credit+1.5
Liquidity-1.0
Inflation-1.2
Commodities+0.5
Interest Rates-0.5

Valuation

Dividend yield3.37%
PEG Ratio17.80
Price to sales2.87
P/E Ratio17.80
Enterprise Value to Revenue5.15
Price to book1.99

Upcoming events

Next earnings dayApril 24, 2025
Next dividend day—
Ex. dividend dayJune 13, 2025

News

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research (July 10, 2025)
EXEL or ARGX: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research (July 3, 2025)
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.

Zacks Investment Research (July 2, 2025)
Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2

Nasdaq is flat in first-half 2025, but SFM, RGLD, TRI, WWD and EXEL are soaring, each up over 20% and primed for the second half.

Zacks Investment Research (June 24, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free